R. Sylvester, A. Van-der-meijden, and W. Oosterlinck, Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials, European Urology, vol.49, issue.3, pp.466-473, 2006.
DOI : 10.1016/j.eururo.2005.12.031

P. Malmstrom, R. Sylvester, and D. Crawford, An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Gu??rin for Non???Muscle-Invasive Bladder Cancer, European Urology, vol.56, issue.2, pp.247-56, 2009.
DOI : 10.1016/j.eururo.2009.04.038

C. Pfister, M. Roupret, and H. Wallerand, Recommandations en Onco-Urologie 2010 : Tumeurs uroth??liales, Progr??s en Urologie, vol.20, issue.4, pp.255-74, 2010.
DOI : 10.1016/S1166-7087(10)70043-9

R. Sylvester, A. Van-der-meijden, and D. Lamm, Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer:, The Journal of Urology, vol.168, pp.1964-70, 2002.
DOI : 10.1097/00005392-200211000-00016

D. Lamm, B. Blumenstein, and J. Crissman, MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY, The Journal of Urology, vol.163, issue.4, pp.1124-1133, 2000.
DOI : 10.1016/S0022-5347(05)67707-5

K. Taniguchi, S. Koga, and M. Nishikido, Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for superficial bladder cancer, Clinical and Experimental Immunology, vol.157, issue.1, pp.131-136, 1999.
DOI : 10.1097/00005392-199602000-00016

Y. Luo, X. Chen, O. Donnell, and M. , Role of Th1 and Th2 cytokines in BCG-induced IFN-?? production: cytokine promotion and simulation of BCG effect, Cytokine, vol.21, issue.1, pp.17-26, 2003.
DOI : 10.1016/S1043-4666(02)00490-8

A. Bohle, C. Nowc, and A. Ulmer, Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy, J Urol, vol.144, pp.59-64, 1990.

D. Boer, E. , D. Jong, W. Steerenberg, and P. , Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Gu??rin in superficial bladder cancer, Cancer Immunology, Immunotherapy, vol.1, issue.5, pp.306-318, 1992.
DOI : 10.1007/BF01741551

A. Jackson, A. Alexandroff, and R. Kelly, Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Gu??rin (BCG) immunotherapy, Clinical & Experimental Immunology, vol.11, issue.3, pp.369-75, 1995.
DOI : 10.1111/j.1365-2249.1995.tb05560.x

S. Prescott, K. James, T. Hargreave, G. Chisholm, and J. Smyth, Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy, J Urol, vol.144, pp.1248-51, 1990.

T. Ratliff, E. Haaff, and W. Catalona, Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer, Clinical Immunology and Immunopathology, vol.40, issue.2, pp.375-384, 1986.
DOI : 10.1016/0090-1229(86)90043-7

D. Balbay, H. Ozen, and H. Ozkardes, Detection of urinary interleukin-2, interleukin-2 receptor, and tumor necrosis factor levels in patients with superficial bladder tumors after intravesical BCG immunotherapy, Urology, vol.43, issue.2, pp.187-90, 1994.
DOI : 10.1016/0090-4295(94)90042-6

A. Bohle, C. Nowc, and A. Ulmer, Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma, Cytokine, vol.2, issue.3, pp.175-81, 1990.
DOI : 10.1016/1043-4666(90)90013-J

C. Magno, D. Melloni, and A. Gali, The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2, Immunology Letters, vol.81, issue.3, pp.235-243, 2002.
DOI : 10.1016/S0165-2478(02)00040-8

F. Saint, N. Kurth, and P. Maille, Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Gu??rin response of superficial bladder cancer during induction course and maintenance therapy, International Journal of Cancer, vol.62, issue.3, pp.434-474, 2003.
DOI : 10.1002/ijc.11352

E. Watanabe, H. Matsuyama, and K. Matsuda, Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Gu???rin immunotherapy for carcinoma in situ of the bladder, Cancer Immunology, Immunotherapy, vol.52, issue.8, pp.481-487, 2003.
DOI : 10.1007/s00262-003-0384-9

M. Sanchez-carbayo, M. Urrutia, R. Romani, M. Herrero, J. Gonzalez-de-buitrago et al., Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG, Anticancer Res, vol.21, pp.3041-3048, 2001.

M. Eto, H. Koga, H. Noma, A. Yamaguchi, Y. Yoshikai et al., Importance of Urinary Interleukin-18 in Intravesical Immunotherapy with Bacillus Calmette-Gu??rin for Superficial Bladder Tumors, Urologia Internationalis, vol.75, issue.2, pp.114-122, 2005.
DOI : 10.1159/000087163